Arbitration Panel Rules Operon Must Pay Qiagen $2.1M | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Operon Biotechnologies must pay Qiagen $2.1 million as a result of an arbitration panel ruling, Qiagen disclosed in a regulatory filing.

In its quarterly earning document filed with the US Securities and Exchange Commission earlier this month, Qiagen said that the arbitration panel ruled in its favor in a supply agreement dispute between the two companies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.